Archie Cochrane's challenge: can periodically updated reviews of all randomised controlled trials relevant to neurology and neurosurgery be produced?

Counsell, Carl; Fraser, H; Sandercock, Peter

doi:10.1136/jnnp.57.5.529

Cited by 12 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51 An international collaborative group called the Cochrane Collaboration was formed in the early 1990s with the specified goal of preparing, maintaining, and disseminating up-to-date reviews of RCTs in healthcare research. 28,50,69,175 In 1992, an influential metaanalysis demonstrated that streptokinase could have been proven effective in reducing the mortality rate after myocardial infarction after only eight RCTs had been performed, and that 25 subsequent RCTs published over a 15-year period had not materially altered that assessment. Conflict between a metaanalysis and a subsequent large RCT on the same question first arose in the case of intravenously administered magnesium after myocardial infarction; the metaanalysis suggested magnesium's efficacy, but large RCTs published later disproved this.…”

Section: Overviewmentioning

confidence: 99%

“…The Cochrane Collaboration is an international group dedicated to the systematic review of all RCT literature. 28,50,69,175,207 Beginning in 2006, reviews of the accuracy of diagnostic tests are also planned. This group maintains a database of systematic reviews compiled under its auspices.…”

Section: Identifying Published Systematic Reviewsmentioning

confidence: 99%

“…28,50,69,175 The number of completed systematic reviews is growing rapidly (Ͼ 2300 as of July 2005), and abstracts of completed reviews and summaries of proposed reviews are available for searching through http://www.update-sofware. com/cochrane/cochrane-frame.html.…”

Section: The Cochrane Collaborationmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Synthesizing medical evidence: systematic reviews and metaanalyses

Barker

Carter²

2005

FOC

View full text Add to dashboard Cite

Systematic reviews and metaanalyses have become increasingly popular ways of summarizing, and sometimes extending, existing medical knowledge. In this review the authors summarize current methods of performing meta-analyses, including the following: formulating a research question; performing a structured literature search and a search for trials not published in the formal medical literature; summarizing and, where appropriate, combining results from several trials; and reporting and presenting results. Topics such as cumulative and Bayesian metaanalysis and metaregression are also addressed. References to textbooks, articles, and Internet resources are also provided. The goal is to assist readers who wish to perform their own metaanalysis or to interpret critically a published example.

show abstract

Section: Overviewmentioning

confidence: 99%

Section: Identifying Published Systematic Reviewsmentioning

confidence: 99%

Section: The Cochrane Collaborationmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Synthesizing medical evidence: systematic reviews and metaanalyses

Barker

Carter²

2005

FOC

View full text Add to dashboard Cite

show abstract

“…The drug has temporary authorization in France for ambulatory patients with RR MS who cannot tolerate interferon treatment [4]. Meta-analysis (a systematic search of all relevant trials and aggregation of their results using appropriate statistical methods to derive a synthetic best estimate of treatment effect) has been proposed to support clinical practice [5, 6]. …”

Section: Introdutionmentioning

confidence: 99%

Meta-Analysis of Clinical Trials with Copolymer 1 in Multiple Sclerosis

Mantia¹,

Milanese²,

D'Amico³

2000

Eur Neurol

View full text Add to dashboard Cite

Glatiramer acetate (copolymer 1) was licensed in the USA in 1996 for the treatment of relapsing-remitting multiple sclerosis. In order to assess its efficacy, a meta-analysis of all randomized controlled trials was performed. Two double-blind studies, accounting for a total number of 299 patients, contribute to this analysis. Patients undergoing the treatment have decreased probability of relapse at 12 months (OR 0.17, 95% CI 0.05–0.51, p = 0.002) and of unsustained progression of disability at 24 and 35 months (OR 0.57, 95% CI 0.34–0.95, p = 0.031, and OR 0.50, 95% CI 0.28–0.90, p = 0.019). These data suggest that glatiramer acetate represents an alternative to interferon treatment in relapsing-remitting multiple sclerosis. However, further evidence of efficacy is required to justify its use in clinical practice.

show abstract